Hambro Perks’ Leaders Fund is our flagship primary venture capital fund, targeting Seed and Series A technology companies in the UK and Europe. With this fund we focus on the four key pillars of fintech, digital health, B2B SaaS and consumer technologies.

With decades of combined investing experience, our team works with talented founders and entrepreneurs to support them as they become business leaders, innovating with game-changing products to help lead their industries in new directions, and have a positive impact on the world.

The Hambro Perks Growth EIS Fund offers eligible individuals, and other entities, the chance to co-invest alongside Hambro Perks in high growth, unlisted companies while benefitting from tax reliefs under the UK’s Enterprise Investment Scheme (EIS).

HP Growth EIS targets pre-seed and seed investments in UK technology companies, again focusing on the four key pillars of fintech, digital health, B2B SaaS and consumer technologies.

Hambro Perks Access Fund is a direct secondaries fund, investing in a diversified portfolio of secondary equity positions in growth technology businesses. The Access Fund has pan-European mandate.

The Access Fund offers selective liquidity to founders and early investors in companies which have achieved clear product market fit and reached the growth stage, but have not yet achieved an exit. The investment provided by this Fund has allowed founders to de-risk their positions, early investors to recoup their capital and employees to access liquidity in option pools.

HP Environmental Technologies Fund invests in emerging environmental technologies working to solve some of the most important environmental challenges faced by the world today.

The Fund was seeded through the secondary purchase of a portfolio of seven leading environmental technology companies and seeks primary investment opportunities that arise from efforts to reduce our impact on the planet and move towards solving important environmental challenges.

Hambro Perks Special Opportunities Fund was raised to acquire secondary stakes in a portfolio of innovative, high-growth technology and healthcare companies in the UK and US. The portfolio currently comprises stakes in 11 companies operating in healthcare, biotechnology and life sciences.

Hambro Perks holds a number of investments through its own balance sheet. These balance sheet investments include stakes in leading complementary funds as well as innovative technology businesses.

The Hambro Perks Oryx Fund is a seed fund making primary investments in seed stage companies in the Middle East and North Africa (MENA) region.

Hambro Perks Acquisition Company Ltd (“HPAC”) is a special purpose acquisition vehicle sponsored by Hambro Perks which listed on the London Stock Exchange in November 2021. HPAC is focused on long-term value creation through the acquisition of a leading, private, tech-enabled business that is appropriate for public market ownership.